NYSEAMERICAN:RNN - Rexahn Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.02 -0.01 (-0.97 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$1.02
Today's Range$1.00 - $1.04
52-Week Range$1.00 - $2.70
Volume179,047 shs
Average Volume256,014 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

Receive RNN News and Ratings via Email

Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:RNN
Previous SymbolNYSEMKT:RNN
CUSIPN/A
Phone+1-240-2685300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees17
Outstanding Shares37,520,000
Market Cap$0.00
OptionableOptionable

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) posted its quarterly earnings data on Monday, November, 5th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.00. View Rexahn Pharmaceuticals' Earnings History.

When is Rexahn Pharmaceuticals' next earnings date?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Rexahn Pharmaceuticals.

What price target have analysts set for RNN?

4 analysts have issued 1 year target prices for Rexahn Pharmaceuticals' shares. Their predictions range from $8.00 to $17.00. On average, they expect Rexahn Pharmaceuticals' stock price to reach $12.50 in the next year. This suggests a possible upside of 1,125.5% from the stock's current price. View Analyst Price Targets for Rexahn Pharmaceuticals.

What is the consensus analysts' recommendation for Rexahn Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rexahn Pharmaceuticals.

What are Wall Street analysts saying about Rexahn Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rexahn Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating but are lowering our price target to $17 from $19.50. The factors impacting our valuation include: (1) change to base year; (2) adjustment to fully diluted share count of of October 2018 equity raise; and (3) increasing our chance of success for RX-3117 in first-line pancreatic cancer from 20% to 25%. Our target is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, RX-3117, and RX-5902 (Supinoxin)." (12/6/2018)
  • 2. According to Zacks Investment Research, "REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. " (10/23/2018)

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

News stories about RNN stock have trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Rexahn Pharmaceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a decrease in short interest during the month of November. As of November 30th, there was short interest totalling 910,977 shares, a decrease of 1.3% from the November 15th total of 922,953 shares. Based on an average trading volume of 141,624 shares, the days-to-cover ratio is currently 6.4 days. Approximately 2.4% of the shares of the company are short sold. View Rexahn Pharmaceuticals' Current Options Chain.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:
  • Dr. Ely Benaim, Chief Medical Officer (Age 57)
  • Dr. Lisa Elizabeth Nolan, Chief Bus. Officer (Age 56)
  • Mr. Douglas J. Swirsky C.F.A., C.P.A., CPA, CFA, CEO, Pres, CFO, Corp. Sec. & Director (Age 49)
  • Dr. Andrew Eisen M.D., VP of Translational Medicine
  • Dr. Madhukar H. Trivedi M.D., Consultant

How do I buy shares of Rexahn Pharmaceuticals?

Shares of RNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of RNN stock can currently be purchased for approximately $1.02.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is https://rexahn.com/cms/.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.


MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEAMERICAN RNN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  490
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe RNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel